Reclassification of chronic pain as a disease may be helpful because patients with chronic
pain require significant treatment and rehabilitation with a clear diagnosis. This can help …

BACKGROUND:: A new transdermal delivery system (TDS) for the rate-controlled systemic
delivery of buprenorphine is available in 3 patch strengths, with release rates of 35, 52.5 …

BACKGROUND Buprenorphine is a partial opioid agonist with high binding affinity at the mu-
opioid receptor. If buprenorphine is given while full opioid agonists occupy the mu-opioid …

OBJECTIVE: The present randomized, double-blinded, crossover study compared the
efficacy and safety of a seven-day buprenorphine transdermal system (BTDS) and placebo …

Aims Buprenorphine is marketed in a sublingual formulation for treatment of opioid
dependence. A transdermal formulation has been developed that may provide extended …

Background Chronic pain is associated with decreased quality of life and is one of the most
common reasons adults seek medical care, making treatment imperative for many aspects of …

Despite the increasing clinical use of transdermal buprenorphine, questions have persisted
about the possibility of a ceiling effect for analgesia, its combination with other μ‐opioid …

The aim of this study was to prospectively evaluate the frequency, indications, outcomes,
and predictive factors associated with opioid switching, using a protocol that had been …

Aim of the study To compare analgesia and adverse effects during oral morphine and
oxycodone and transdermal fentanyl and buprenorphine administration in cancer patients …

In Germany and many other countries, buprenorphine has been used for a long time for the
management of pain in both cancer and non-cancer patients. Although a transdermal …